Vitrification was not one invention. It emerged as researchers solved a sequence of different problems across cells, embryos, organs and, eventually, human biostasis.
The objective sounds simple: cool water-rich tissue into a glass without forming damaging ice.
The implementation is not simple. Cryoprotectants can be toxic. Loading them can distort cells. Large objects cool unevenly, accumulate stress and are much harder to rewarm.
Modern procedures are therefore systems, not recipes. Their quality depends on chemistry, perfusion, temperature, timing, geometry and measurement working together.
Before vitrification: cold created a second injury
Early cryopreservation largely meant freezing. Cooling slowed chemistry, but water crystallised into ice.
Ice excludes salts and other solutes into the remaining liquid. Cells can therefore experience mechanical displacement, extreme solute concentrations, dehydration and membrane injury simultaneously.
Cooling faster can make crystals smaller, but ordinary water requires extraordinary rates to become glass without chemical assistance. That works only for extremely thin samples.
The historical problem was not merely reaching a low temperature. It was reaching it without allowing water to reorganise into damaging crystals.
1937 to 1938: the first kinetic vitrification experiments
Basile Luyet proposed vitrification as a biological preservation strategy in 1937.
In 1938, Luyet and Eugene Hodapp reported recovery of motility in frog sperm exposed to liquid air after dehydration with concentrated sucrose.
The original experiment depended on microscopic films and extreme cooling speed. It demonstrated a physical possibility, not a scalable organ protocol.
This approach is now called kinetic vitrification: outrun crystallisation by removing heat faster than ice can nucleate and grow.
Scale defeats it. Surface area grows more slowly than volume, so the centre of a large sample cannot follow the surface quickly enough.
1949: glycerol changes the problem
Christopher Polge, Audrey Smith and Alan Parkes discovered in 1949 that glycerol could protect spermatozoa during low-temperature preservation.
Their Nature report established the practical importance of penetrating cryoprotective agents.
These molecules enter cells, bind water and reduce the amount of ice formed at a given temperature. They also reduce damaging solute concentration during freezing.
The discovery transformed cryobiology because cooling rate was no longer the only control variable. Chemical composition could reshape the phase behaviour of water.
It also introduced a new optimization problem. More cryoprotectant suppresses ice more effectively, but increases chemical and osmotic injury.
1959 to 1968: more agents and stepwise loading
In 1959, James Lovelock and Marcus Bishop reported that dimethyl sulfoxide protected several cell types against freezing injury.
DMSO crossed some membranes more readily than glycerol. It expanded the range of cells that could be cryoprotected and remains widely used in laboratory and clinical cryopreservation.
John Farrant then explored raising cryoprotectant concentration while lowering temperature, keeping tissue in a concentrated liquid without deliberately forming ice.
This anticipated a core feature of modern protocols: load cryoprotectant in steps, at low temperature, instead of exposing warm tissue to full concentration at once.
Stepwise loading limits osmotic shock. Lower temperature reduces many chemical reaction rates and can make otherwise damaging exposure more tolerable.
In 1968, experiments showed red blood cells could reach liquid-nitrogen temperature without visible ice at sufficiently high glycerol concentration.
The conceptual pieces were present. What remained missing was a practical way to apply them to complex, vascularised tissue.
1984: vitrification becomes an organ strategy
The 1984 paper “Vitrification as an Approach to Cryopreservation” reframed vitrification as a serious route to organ banking.
The strategy was sometimes called equilibrium vitrification. Instead of requiring impossible cooling speed, use enough cryoprotectant to make the critical cooling rate achievable in a larger system.
That shift exposed three coupled constraints:
- The solution must resist ice at attainable cooling and warming rates.
- The organ must tolerate loading and unloading that solution.
- The cryoprotectant must reach every region before cooling begins.
A formulation could perform beautifully in a test tube and fail in an organ because vascular resistance, diffusion distance or toxicity changed the result.
1985: living embryos return from a glassy state
William Rall and Gregory Fahy reported ice-free cryopreservation of mouse embryos at -196°C in 1985.
This was a decisive biological demonstration. Living nucleated mammalian cells could survive cooling and rewarming through a wholly vitrified state.
Embryos are still tiny. Their temperature and concentration can change quickly and uniformly compared with an adult organ.
The result validated the method while making the scale problem more visible.
The scale problem splits into four problems
1. Cryoprotectant toxicity
The concentration needed for vitrification can disrupt proteins, membranes and cellular metabolism. Toxicity depends on agent, concentration, temperature, exposure time and tissue type.
This means “less toxic” is not a property of one molecule alone. It is a property of the complete loading and unloading protocol.
2. Osmotic stress
Adding concentrated solution pulls water out of cells. Removing it can drive water back in too quickly.
Modern protocols use concentration ramps, carrier solutions, temperature control and non-penetrating solutes to keep volume excursions within tolerable limits.
3. Uneven delivery
An organ is not a container of uniform liquid. Cryoprotectant travels through vessels, crosses capillary walls and diffuses through tissue.
Clots, oedema, vascular disease, ischaemia and the blood-brain barrier can leave some regions below the concentration required to suppress ice.
This is why modern perfusion measures pressure, flow, temperature and venous concentration rather than relying on solution volume alone.
4. Thermal gradients
A large object cools from outside inward. Different temperatures cause different rates of contraction.
Near and below the glass transition, the material cannot relax stress quickly. If stress exceeds its mechanical strength, fractures can form.
The solution was controlled-rate cooling, annealing near Tg and slower descent through the glassy region. These principles now shape computer-controlled human cooldown.
1990s and 2000s: mixtures replace single-agent thinking
No single cryoprotectant optimized every requirement. Researchers increasingly combined penetrating agents so each could contribute without reaching its worst individual concentration.
Carrier solutions controlled ions, pH and osmotic conditions. Non-penetrating polymers influenced tissue water and vascular behaviour.
Synthetic ice blockers targeted heterogeneous ice nucleation and growth. They reduced dependence on brute-force cryoprotectant concentration alone.
Solutions such as VS55 and later M22 represented systems engineering: multiple agents, ice blockers and carefully designed carrier chemistry paired with defined perfusion and thermal protocols.
A 2004 review of organ vitrification describes advances in toxicity reduction, chilling injury, nucleation control and organ perfusion.
The important advance was not that toxicity disappeared. Researchers learned to distribute the burden across chemistry, time and temperature.
Rabbit-kidney experiments: important and easy to overstate
Rabbit-kidney work demonstrated that a vascularised mammalian organ could be loaded with a complex vitrification solution, cooled to a glassy state, rewarmed and transplanted.
One reported kidney supported a rabbit as its sole functioning kidney for an extended period.
That result matters because it crossed from microscopic samples into organ function. It did not establish a reliable clinical procedure.
The later literature notes that long-term transplant success was not reproducibly achieved. Distribution, toxicity and conventional surface rewarming remained limiting.
This is the correct epistemic status: a significant proof of principle with a reproducibility and scale problem.
2015: preservation quality becomes visible at synaptic scale
Aldehyde-stabilized cryopreservation combined chemical fixation, cryoprotectant perfusion and vitrification in rabbit and pig brains.
The 2015 study reported clear membranes, synapses, vesicles, myelin and intracellular structures after rewarming and preparation for electron microscopy.
It demonstrated that excellent neural ultrastructure could survive an ice-free storage cycle across large brains.
It did not demonstrate viable recovery. Aldehyde fixation intentionally cross-links biological material and is incompatible with ordinary restoration of living function.
The experiment therefore answered a structural question, not the complete revival question.
Its broader contribution was methodological: preservation should be judged by inspecting the structures of interest, not merely by observing that a sample looks glassy.
2023: nanowarming solves rewarming in rat kidneys
Cooling is only half of reversible cryopreservation. Rewarming is often harder.
If warming is too slow, ice can grow during devitrification. If heat arrives mainly from the surface, thermal gradients can fracture the organ.
Nanowarming addresses both problems by distributing iron-oxide nanoparticles through the vasculature and heating them with an alternating radiofrequency magnetic field.
In 2023, researchers vitrified rat kidneys, stored them for up to 100 days, nanowarmed them and transplanted them.
The recovered kidneys restored life-sustaining renal function in recipients without native kidneys during the reported follow-up.
The achievement depended on more than warming. The team changed to a less toxic formulation and modelled cryoprotectant loading to improve tissue concentration.
This is a recurring lesson in vitrification history: solving one bottleneck reveals the next one, and successful recovery requires the whole chain.
2024 to 2026: larger physical systems and functional neural tissue
In 2024, researchers reported physical vitrification at human-organ scale in 0.5 to 3 litre systems.
They combined internal thermometry, annealing, controlled cooling and micro-CT inspection. They also demonstrated nanowarming in volumes up to 2 litres.
The largest demonstrations were primarily physical. Avoiding visible ice and cracks is necessary, but it does not establish biological recovery of a human-sized organ.
In 2026, a PNAS study reported short-term functional recovery of adult mouse hippocampal tissue after vitrification and rewarming.
The study measured morphology, mitochondrial responsiveness, neuronal excitability, synaptic transmission and long-term potentiation.
It involved mouse brain slices and low-yield whole-brain preparations, not a human brain. Its significance is narrower and still substantial.
It showed that adult mammalian neural tissue can recover electrophysiological functions after molecular mobility has stopped in a vitreous state.
Human biostasis inherits the science under harder conditions
Organ-banking experiments begin with healthy tissue, controlled timing and planned access to the vasculature.
Human biostasis begins after legal death. Illness, warm ischaemia, clotting, oedema, transport and vascular disease can all impair cryoprotectant delivery.
The immediate objective is structural preservation for possible future repair, not present-day reversible transplantation.
This difference is why laboratory claims cannot be copied directly into claims about patients.
How Tomorrow.bio adapted vitrification for field conditions
Tomorrow.bio moved whole-body cryoprotective perfusion into specialized ambulances. The procedure can begin near the patient instead of waiting for transport to Switzerland.
This changes an important input that chemistry cannot repair: the amount of ischaemia before perfusion.
The current protocol uses VM-1-based solution chemistry adapted for field cryoprotection and subsequent dry-ice transport.
An EBF research programme has tested VM-1 under simulated postmortem conditions, including three hours of warm ischaemia.
The programme measured venous refractive index, perfusion time, weight change, brain shrinkage and ice formation while testing changes in perfusate and procedure.
This is the practical frontier for human cases: not whether an ideal solution can vitrify, but how well a real ischaemic patient can be perfused.
Measurement became part of the procedure
Early vitrification research often established success through transparency, calorimetry, X-ray diffraction, survival or function after rewarming.
Human biostasis cannot use recovery as a present-day endpoint. It therefore needs non-destructive and sampled measures of preservation quality.
Tomorrow.bio CT scans every patient at the same liquid-nitrogen temperature to estimate cryoprotectant distribution and identify ice or macroscopic defects under standardized conditions.
With separate consent, neural microsamples can support electron-microscopy assessment of membranes, synapses and local ultrastructure.
These methods and their limits are described in biostasis quality-check procedures.
Measurement changes development itself. When a failure becomes visible and comparable across cases, chemistry and protocol changes can target it.
What has improved, and what has not been solved
Modern vitrification has achieved several things that early freezing could not:
- Ice-free preservation of many cells, embryos and small tissues.
- Functional recovery of vitrified animal organs in defined experiments.
- Synaptic-scale structural preservation in fixed mammalian brains.
- Computer-controlled cooling and annealing of larger systems.
- Volumetric rewarming through technologies such as nanowarming.
- CT and electron-microscopy methods for measuring real preservation outcomes.
It has not produced reversible human whole-body cryopreservation.
The remaining problems include postmortem ischaemia, uneven perfusion, cryoprotectant toxicity, blood-brain-barrier effects, whole-body thermal gradients, fracture avoidance and safe uniform rewarming.
Even successful structural preservation would leave the future problems of repair, revival and treatment of the original cause of death.
Those distinctions are developed in technical challenges for reversible cryopreservation.
TL;DR: Vitrification improved through better cryoprotectants, perfusion, ice control, cooling, rewarming and structural measurement. Some problems are solved at small scales, while whole-human reversibility remains unsolved.
Take the cryopreservation guide with you
Get a practical guide to the procedure, its limits and the decisions involved.
Loading the interactive tool...
Further reading